IN2015DN02729A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02729A
IN2015DN02729A IN2729DEN2015A IN2015DN02729A IN 2015DN02729 A IN2015DN02729 A IN 2015DN02729A IN 2729DEN2015 A IN2729DEN2015 A IN 2729DEN2015A IN 2015DN02729 A IN2015DN02729 A IN 2015DN02729A
Authority
IN
India
Prior art keywords
leech
treat
methods
saliva
extract
Prior art date
Application number
Inventor
Ahmed; Merzouk
Abbas Mohammad; Ghawi
Abdualrahman M ; Abdualkader
Mohamed; Alaama
Original Assignee
Biopep Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopep Solutions Inc filed Critical Biopep Solutions Inc
Publication of IN2015DN02729A publication Critical patent/IN2015DN02729A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/62Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/033Rearing or breeding invertebrates; New breeds of invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agronomy & Crop Science (AREA)
  • Microbiology (AREA)

Abstract

Methods are provided for isolating and using a whole- saliva leech extract. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech , the inducing including placing the leech in an environment having a temperature of less than about 0°C; and , collecting an unrefined , whole saliva in the regurgitation of the cooled leech. The methods can include revitalizing the leech by warming it at a temperature ranging from about 5°C to about 40°C. Stable , lyophilized , whole -saliva extracts of a leech are also provided , the extract having a stable activity when stored for use at a temperature below about -20°C, the extract maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treat liquid tumors , treat diabetes, treat a viral disease, treat a parasitic disease , treat an antibacterial disease , or serve as an anti -oxidant.
IN2729DEN2015 2012-09-17 2013-09-17 IN2015DN02729A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261701735P 2012-09-17 2012-09-17
US13/624,847 US8685462B1 (en) 2012-09-17 2012-09-21 Whole, leech saliva product and applications thereof
PCT/IB2013/002848 WO2014049447A2 (en) 2012-09-17 2013-09-17 A whole, leech saliva extract

Publications (1)

Publication Number Publication Date
IN2015DN02729A true IN2015DN02729A (en) 2015-09-04

Family

ID=48876315

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2729DEN2015 IN2015DN02729A (en) 2012-09-17 2013-09-17

Country Status (10)

Country Link
US (17) US8784896B2 (en)
EP (1) EP2895178B1 (en)
JP (1) JP6220398B2 (en)
CN (1) CN104837495A (en)
AU (1) AU2013322269B2 (en)
CA (1) CA2882533A1 (en)
ES (1) ES2710126T3 (en)
IN (1) IN2015DN02729A (en)
MX (1) MX362375B (en)
WO (1) WO2014049447A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784896B2 (en) 2012-09-17 2014-07-22 Biopep Solutions, Inc Antioxidant therapy with a whole, leech saliva extract
KR101341289B1 (en) * 2013-07-09 2013-12-12 한선대 Extraction method of leech saliva
CN104151425B (en) * 2014-08-15 2017-02-08 周维海 Large-scale production method for natural hirudin
CN104365560A (en) * 2014-10-29 2015-02-25 颍上县永祥旱粮研究所 Leech breeding method
CN105594666B (en) * 2015-12-25 2020-04-03 贵州信邦制药股份有限公司 Breeding method for rapidly increasing antithrombin activity of leeches
CN105418756B (en) * 2015-12-25 2018-12-21 汤浩强 A kind of method that leech saliva repeats extraction
CN108210523A (en) * 2016-12-09 2018-06-29 江苏小潘园生态农业科技发展有限公司 A kind of production method of leech wine
CN107129962B (en) * 2017-05-18 2019-03-05 中国计量大学 A kind of primary culture method of Hirudo japonica salivary gland cell
CN107519036A (en) * 2017-09-06 2017-12-29 深圳肽之妃科技有限公司 A kind of striae of pregnancy spray containing polypeptide and preparation method thereof
CN107796183A (en) * 2017-11-17 2018-03-13 广西远程水蛭养殖有限公司 Leech drying means
CN109528773A (en) * 2019-01-15 2019-03-29 昆明学院 Leech saliva is preparing the application in analgesic
CN109662984B (en) * 2019-02-13 2022-07-26 昆明医科大学 Application of laggera pterodonta and rosemary extract in medicine for resisting type II dengue virus
US10787338B1 (en) 2019-08-30 2020-09-29 Blazing Spools LLC Spool device and related methods
CN112915106A (en) * 2021-02-05 2021-06-08 张虎山 Preparation and application of tumor immune microenvironment regulator
CN113577821B (en) * 2021-07-07 2022-08-30 三峡大学 Repeated extraction device and method for hirudin in living body
CN118005739B (en) * 2024-04-09 2024-06-21 南京华盖制药有限公司 Polypeptide APH229 of drug-resistant strain, preparation method and application thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588587A (en) 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
JP2566934B2 (en) 1985-08-10 1996-12-25 バイオフア−ム(ユ−ケイ)リミテツド Collagen-specific enzyme having platelet aggregation inhibitory action
US4832849A (en) 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii
IL86857A (en) * 1988-06-24 1994-04-12 Yissum Res Dev Co Platelet-aggregating inhibitory agents from leech saliva and pharmaceutical preparations containing the same
GB8826428D0 (en) * 1988-11-11 1988-12-14 Biopharm Ltd Antithrombin
AU624962B2 (en) * 1989-06-20 1992-06-25 Merrell Dow Pharmaceuticals Inc. Ghilanten: antimetastatic principle from the south american leech, haementeria ghilanii
ZA904622B (en) 1989-06-20 1991-03-27 Merrell Dow Pharma Ghilanten:antimetastatic principle from the south american leech,haementeria ghilanii
DE4103649A1 (en) 1991-02-07 1992-08-13 Basf Ag NEW ANTICOAGULATORY EFFECTIVE PEPTIDE
AU659432B2 (en) 1991-03-08 1995-05-18 Novartis Ag A method for the inhibition or prevention of tumor cell metastasis with hirudin
DE4209110A1 (en) 1991-11-26 1993-05-27 Basf Ag NEW THROMBININHIBITOR PROTEINS FROM COUNTRY LEAVES
DE4234921A1 (en) 1992-10-16 1994-04-21 Basf Ag New blood coagulation protein from Haemadipsa sylestris
EP0696198B1 (en) 1993-04-09 2001-01-17 Bio-Technology General Corporation Novel polypeptide having factor xa inhibitory activity
GB9309509D0 (en) 1993-05-07 1993-06-23 Merck Patent Gmbh Thrombin inhibitors
WO1995004750A1 (en) 1993-08-09 1995-02-16 Athena Neurosciences, Inc. Tick derived protease inhibitor
US6270808B1 (en) * 1995-11-13 2001-08-07 Gerard Voerman Anti-viral isolates obtainable from leeches
US5866120A (en) 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
US6610292B2 (en) 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
EP0875564A1 (en) 1997-05-02 1998-11-04 Gerard Voerman Biologically active extract from the leech 'Limnatis nilotica'
SE512633C2 (en) 1997-07-09 2000-04-17 Cecilia Johnsson Use of hyaluronidase for the reduction of inflammatory cell infiltrates
CA2376467A1 (en) 1999-06-12 2000-12-21 Merck Patent Gesellschaft Mit Beschraenkter Haftung Hyaluronidase from the hirudinaria manillensis, isolation, purification and recombinant method of production
WO2003005955A2 (en) * 2001-07-09 2003-01-23 Aphton Corporation Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
CN1273012C (en) * 2003-01-15 2006-09-06 周维海 Culture of hiruto and extraction of hirutin
CN101230086A (en) * 2007-01-22 2008-07-30 广东海洋大学 Technique for producing hirudin by using poecilobdella manillensis saliva as raw material
WO2009018640A1 (en) 2007-08-07 2009-02-12 Universidade Federal De São Paulo Unifesp Use of platelet aggregation and coagulation inhibitors isolated from bauhinia sp.
US20110070184A1 (en) * 2008-03-24 2011-03-24 Carolus Therpeutics, Inc. Methods and compositions for treating atherosclerosis and related condidtions
EP2316465A1 (en) 2009-10-15 2011-05-04 Centre National De La Recherche Scientifique Use of extract of leeches' saliva as anti-bacterial agent for the manufacture of different compositons
CN102258771A (en) 2011-07-13 2011-11-30 中国药科大学 Application of recombinant hirudin in preventing and treating diabetic cataract
US8784896B2 (en) 2012-09-17 2014-07-22 Biopep Solutions, Inc Antioxidant therapy with a whole, leech saliva extract
CN102964446B (en) * 2012-11-28 2014-08-13 周维官 Method for repeatedly extracting natural hirudin from live vampire leech

Also Published As

Publication number Publication date
US20160120914A1 (en) 2016-05-05
ES2710126T3 (en) 2019-04-23
US9480720B1 (en) 2016-11-01
AU2013322269A1 (en) 2015-03-05
US20150099006A1 (en) 2015-04-09
US8932642B2 (en) 2015-01-13
AU2013322269B2 (en) 2018-05-31
US20150182562A1 (en) 2015-07-02
US10064897B2 (en) 2018-09-04
US9005667B1 (en) 2015-04-14
EP2895178B1 (en) 2018-11-07
MX362375B (en) 2019-01-14
WO2014049447A3 (en) 2014-06-19
JP6220398B2 (en) 2017-10-25
US8784896B2 (en) 2014-07-22
US20140079800A1 (en) 2014-03-20
US20150086645A1 (en) 2015-03-26
US20140079799A1 (en) 2014-03-20
US20140079798A1 (en) 2014-03-20
US9433649B2 (en) 2016-09-06
US9017732B1 (en) 2015-04-28
US20150359825A1 (en) 2015-12-17
US20170239301A1 (en) 2017-08-24
CA2882533A1 (en) 2014-04-03
EP2895178A2 (en) 2015-07-22
US9265803B2 (en) 2016-02-23
US8685462B1 (en) 2014-04-01
US20140363518A1 (en) 2014-12-11
US20160331790A1 (en) 2016-11-17
US20150196607A1 (en) 2015-07-16
US9149498B2 (en) 2015-10-06
US9265802B2 (en) 2016-02-23
US8501241B1 (en) 2013-08-06
WO2014049447A2 (en) 2014-04-03
US8962034B2 (en) 2015-02-24
US9144587B2 (en) 2015-09-29
EP2895178A4 (en) 2016-05-25
MX2015003352A (en) 2015-10-22
US20160120913A1 (en) 2016-05-05
JP2015528491A (en) 2015-09-28
CN104837495A (en) 2015-08-12
US9433648B2 (en) 2016-09-06
US20160331789A1 (en) 2016-11-17
US20140356448A1 (en) 2014-12-04
US9597361B2 (en) 2017-03-21
US8790711B2 (en) 2014-07-29
US20150359826A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
IN2015DN02729A (en)
PH12017501306A1 (en) Inhibitors of histone demethylases
MX2013006040A (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis.
MX365939B (en) Nuclear transport modulators and uses thereof.
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
CO6440531A2 (en) 2-ACETAMIDO-5-ARIL-1,2,4-SUBSTITUTED TRIAZOLONES AND ITS USE
NZ702663A (en) Nuclear transport modulators and uses thereof
JO3776B1 (en) PHARMACEUTICAL COMBINATIONS of a CDK4/6 inhibitor and B-Raf inhibitor
MX2019008122A (en) Heterocycle amines and uses thereof.
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
MX2013004061A (en) Cyclosporin analogs.
BR112012028711A2 (en) methods for making an oil-in-water emulsion, for preparing a vaccine kit and for redistillating a composition comprising 99% squalene or more, as well as oil-in-water emulsion and kit
BR112012032008A2 (en) s100a4 antibodies and therapeutic uses thereof
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
MX2014000829A (en) Polyacrylate-based active compound-comprising particles.
MX2013004062A (en) Cyclosporin analogs.
SA113340494B1 (en) Composition for treating metabolic disorders
WO2014165723A3 (en) Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
MX2013010308A (en) 2,4 substituted pyrimidinediamines for use in discoid lupus.
WO2014100857A8 (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
MX2014006574A (en) Acamprosate formulations, methods of using the same, and combinations comprising the same.
WO2012108748A3 (en) Composition and cosmetic composition for treating brain cancer comprising albizzia julibrissin extract
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
UA41802U (en) Composition for treating sarcoptoidosis of animals
MY187299A (en) An extract of tinospora crispa and use as an antihypercholesterolemic agent